Literature DB >> 19264779

Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon.

Shuichi Kinpara1, Atsuhiko Hasegawa, Atae Utsunomiya, Hironori Nishitsuji, Hiroyuki Furukawa, Takao Masuda, Mari Kannagi.   

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia (ATL), HTLV-1-associated myelopathy/tropical spastic paraparesis, and other inflammatory diseases. Despite such severe outcomes of HTLV-1 infection, the level of HTLV-1 expression in vivo is very low and rapidly increases after transfer of cells to culture conditions. The mechanisms of this phenomenon have remained obscure. In the present study, we found that human and mouse stromal cells, such as epithelial cells and fibroblasts, suppressed HTLV-1 expression in ATL and non-ATL HTLV-1-infected cells. HTLV-1 mRNA and proteins in HTLV-1-infected cells markedly decreased upon coculture with human epithelial-like cells (HEK293T) or mouse embryo fibroblasts (NIH 3T3). When infected cells were reisolated from the cocultures, viral expression was restored to the original level over the following 48 h. Spontaneous induction of HTLV-1 expression in primary ATL cells in the first 24 h of culture was also inhibited by coculture with HEK293T cells. Coculture of HTLV-1-infected cells and HEK293T cells induced type I interferon responses, as detected by beta interferon (IFN-beta) promoter activation and IFN-stimulated gene upregulation. HEK293T-mediated suppression of HTLV-1 expression was partly inhibited by antibodies to human IFN-alpha/beta receptor. NIH 3T3-mediated suppression was markedly abrogated by neutralizing antibodies to mouse IFN-beta. Furthermore, viral expression in HTLV-1-infected cells was significantly suppressed when the infected cells were intraperitoneally injected into wild-type mice but not IFN regulatory factor 7 knockout mice that are deficient of type I IFN responses. These findings indicate that the innate immune system suppresses HTLV-1 expression in vivo, at least through type I IFN.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19264779      PMCID: PMC2682107          DOI: 10.1128/JVI.02564-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes.

Authors:  E Hanon; S Hall; G P Taylor; M Saito; R Davis; Y Tanaka; K Usuku; M Osame; J N Weber; C R Bangham
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

Review 2.  Molecular mechanisms of cellular transformation by HTLV-1 Tax.

Authors:  Ralph Grassmann; Mordechai Aboud; Kuan-Teh Jeang
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

Review 3.  Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-kappa B.

Authors:  K T Jeang
Journal:  Cytokine Growth Factor Rev       Date:  2001 Jun-Sep       Impact factor: 7.638

Review 4.  Multiple viral strategies of HTLV-1 for dysregulation of cell growth control.

Authors:  M Yoshida
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

5.  Mouse model for the equilibration interaction between the host immune system and human T-cell leukemia virus type 1 gene expression.

Authors:  Rika A Furuta; Kikuya Sugiura; Shigenari Kawakita; Takefumi Inada; Susumu Ikehara; Tadashi Matsuda; Jun-ichi Fujisawa
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Provirus expansion and deregulation of apoptosis-related genes in the spinal cord of a rat model for human T-lymphocyte virus type I-associated myeloneuropathy.

Authors:  Utano Tomaru; Hitoshi Ikeda; Xiuyun Jiang; Osamu Ohya; Takashi Yoshiki
Journal:  J Neurovirol       Date:  2003-10       Impact factor: 2.643

7.  Depletion and impaired interferon-alpha-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals.

Authors:  Masakatsu Hishizawa; Kazunori Imada; Toshio Kitawaki; Maki Ueda; Norimitsu Kadowaki; Takashi Uchiyama
Journal:  Br J Haematol       Date:  2004-06       Impact factor: 6.998

8.  Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation.

Authors:  Nanae Harashima; Kiyoshi Kurihara; Atae Utsunomiya; Ryuji Tanosaki; Shino Hanabuchi; Masato Masuda; Takashi Ohashi; Fumiyo Fukui; Atsuhiko Hasegawa; Takao Masuda; Yoichi Takaue; Jun Okamura; Mari Kannagi
Journal:  Cancer Res       Date:  2004-01-01       Impact factor: 12.701

9.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

10.  Repression of tax expression is associated both with resistance of human T-cell leukemia virus type 1-infected T cells to killing by tax-specific cytotoxic T lymphocytes and with impaired tumorigenicity in a rat model.

Authors:  Machiko Nomura; Takashi Ohashi; Keiko Nishikawa; Hironori Nishitsuji; Kiyoshi Kurihara; Atsuhiko Hasegawa; Rika A Furuta; Jun-ichi Fujisawa; Yuetsu Tanaka; Shino Hanabuchi; Nanae Harashima; Takao Masuda; Mari Kannagi
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more
  24 in total

1.  Population ecology of heterotypic tumour cell cultures.

Authors:  M Sega; R Chignola
Journal:  Cell Prolif       Date:  2014-08-27       Impact factor: 6.831

Review 2.  Novel Immunotherapies for T Cell Lymphoma and Leukemia.

Authors:  Paola Ghione; Alison J Moskowitz; Nadia E K De Paola; Steven M Horwitz; Marco Ruella
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 3.  How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)?

Authors:  Charles R M Bangham; Lee Ratner
Journal:  Curr Opin Virol       Date:  2015-09-27       Impact factor: 7.090

4.  Alpha interferon restricts human T-lymphotropic virus type 1 and 2 de novo infection through PKR activation.

Authors:  Anne Cachat; Sébastien Alain Chevalier; Sandrine Alais; Nga Ling Ko; Lee Ratner; Chloé Journo; Hélène Dutartre; Renaud Mahieux
Journal:  J Virol       Date:  2013-10-02       Impact factor: 5.103

5.  HTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of cytokine signaling 1 (SOCS1).

Authors:  Stéphanie Olière; Eduardo Hernandez; Agnès Lézin; Meztli Arguello; Renée Douville; Thi Lien-Anh Nguyen; Stéphane Olindo; Gérard Panelatti; Mirdad Kazanji; Peter Wilkinson; Rafick-Pierre Sékaly; Raymond Césaire; John Hiscott
Journal:  PLoS Pathog       Date:  2010-11-04       Impact factor: 6.823

6.  Effect of type-I interferon on retroviruses.

Authors:  Esperanza Gómez-Lucía; Victorio M Collado; Guadalupe Miró; Ana Doménech
Journal:  Viruses       Date:  2009-10-27       Impact factor: 5.048

Review 7.  HTLV-1 and innate immunity.

Authors:  Chloé Journo; Renaud Mahieux
Journal:  Viruses       Date:  2011-08-08       Impact factor: 5.048

8.  The roles of acquired and innate immunity in human T-cell leukemia virus type 1-mediated diseases.

Authors:  Mari Kannagi; Atsuhiko Hasegawa; Ayako Takamori; Shuichi Kinpara; Atae Utsunomiya
Journal:  Front Microbiol       Date:  2012-09-03       Impact factor: 5.640

9.  Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells.

Authors:  Shuichi Kinpara; Mami Kijiyama; Ayako Takamori; Atsuhiko Hasegawa; Amane Sasada; Takao Masuda; Yuetsu Tanaka; Atae Utsunomiya; Mari Kannagi
Journal:  Retrovirology       Date:  2013-05-20       Impact factor: 4.602

10.  Immunopathogenesis of human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: recent perspectives.

Authors:  Mineki Saito; Charles R M Bangham
Journal:  Leuk Res Treatment       Date:  2012-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.